CVS
CVS HealthNYSEHealth CareHealthcare PlansSnapshot 2026-05-08
As of May 8, 2026, CVS has a signal label of "mild_favorable" and a composite score of 15.7. This change is driven by a significant rise in the company momentum score, which increased by 63.6 points to 48.1, along with an improvement in the valuation score, which rose by 17.5 points to 66.7. The valuation label has also changed from "full" to "fair." This information is provisional.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share0.57
- Slope (norm)0.24
- Bonus0.00
Why this rank
Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3
Why this rank
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $1.83 → $1.83 (+0.2% / 30d). 5 raised, 8 cut, 21 covering analysts.
0 upgrades, 0 downgrades / 30d, 6 maintained. 89% of analysts rate Buy.
5 PT revisions / 30d. Avg target 16.7% above current price.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
1 material event in the last 24 months — top 1 listed below.
Stated priorities
3 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Increase cash flow from operationscapital allocationmixed30% progress
5/6: “Raising full-year 2026 guidance: Cash flow from operations guidance to at least $9.5 billion from at least $9.0 billion.”
Why this status
Stated in 3 of last 3 quarters. Cash flow from operations guidance was raised to at least $9.5 billion for 2026, up from $9.0 billion. Despite the increase in guidance, cash from operating activities was negative in 2025-Q4 at -$9.498 billion, indicating limited progress in achieving the target so far.
- 2.Increase adjusted EPS guidancegrowthbehind0% progress
5/6: “Raising full-year 2026 guidance: Adjusted EPS guidance range to $7.30 to $7.50 from $7.00 to $7.20.”
Why this status
Stated in 3 of last 3 quarters. Adjusted EPS guidance was raised to $7.30 to $7.50 for 2026, up from $7.00 to $7.20. However, diluted EPS was negative at -$3.13 in 2025-Q3, indicating challenges in achieving the adjusted EPS target.
- 3.Maintain revenue guidance of at least $400 billiongrowthbehind0% progressprovisional
12/9: “The Company is initiating its 2026 full-year financial guidance as follows: Total revenues of at least $400.0 billion.”
Why this status
Newly stated in 2025-Q4. The company has set a revenue guidance of at least $400 billion for 2026. Revenue for 2025-Q4 was $82.586 billion, indicating a need for significant growth to meet the annual target.
Guidance track record
Insufficient guidance history for this ticker.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 38%; 252d 32%.
Drawdown — Max 1y −16%. Bad day move −3%.
Beta to sector ETF (XLV) — 0.62 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 47/100, drawdown 67/100, beta 62/100, earnings vol —.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- score change · company_momentum_scoreseverity 100
Company momentum rose by 63.6 points (from -15.5 to 48.1).
- score change · composite_insight_scoreseverity 36
Composite insight rose by 18.0 points (from -2.3 to 15.7).
- score change · valuation_scoreseverity 35
Valuation rose by 17.5 points (from 49.2 to 66.7).
- label change · signal_labelseverity 20
Signal changed from 'mixed' to 'mild_favorable'.
- label change · valuation_labelseverity 20
Valuation label changed from 'full' to 'fair'.
As of May 8, 2026, CVS experienced notable changes in its scores and labels. The company momentum score rose by 63.6 points, from -15.5 to 48.1, and the composite insight score increased by 18.0 points, from -2.3 to 15.7. The valuation score also improved by 17.5 points, moving from 49.2 to 66.7. Additionally, the signal label changed from 'mixed' to 'mild_favorable', and the valuation label changed from 'full' to 'fair'.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
Met or beat guidance 100% of the last 2 guided quarters · 5.3% avg surprise
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Increase cash flow from operations
Capital allocationNew since 2026-05-06Focus on raising cash flow from operations to at least $9.5 billion for 2026.
MixedStated in 3 of last 3 quarters. Cash flow from operations guidance was raised to at least $9.5 billion for 2026, up from $9.0 billion. Despite the increase in guidance, cash from operating activities was negative in 2025-Q4 at -$9.498 billion, indicating limited progress in achieving the target so far.
30%CEO/CFO:“Raising full-year 2026 guidance: Cash flow from operations guidance to at least $9.5 billion from at least $9.0 billion.”Multiple sourcesSource dated 2026-05-06Stated 3 of last 8 quartersFirst seen 2026-05-06Show history (3)
- 2026-Q2Multiple sources
“Raising full-year 2026 guidance: Cash flow from operations guidance to at least $9.5 billion.”
- 2026-Q1Multiple sources
“Updated cash flow from operations guidance to at least $9.0 billion.”
- 2025-Q4Multiple sources
“Cash flow from operations guidance of at least $10.0 billion.”
- #2
Increase adjusted EPS guidance
GrowthNew since 2026-05-06Raise adjusted EPS guidance range to $7.30 to $7.50 for 2026.
BehindStated in 3 of last 3 quarters. Adjusted EPS guidance was raised to $7.30 to $7.50 for 2026, up from $7.00 to $7.20. However, diluted EPS was negative at -$3.13 in 2025-Q3, indicating challenges in achieving the adjusted EPS target.
0%CEO/CFO:“Raising full-year 2026 guidance: Adjusted EPS guidance range to $7.30 to $7.50 from $7.00 to $7.20.”Multiple sourcesSource dated 2026-05-06Stated 3 of last 8 quartersFirst seen 2026-05-06Show history (3)
- 2026-Q2Multiple sources
“Raising full-year 2026 guidance: Adjusted EPS guidance range to $7.30 to $7.50.”
- 2026-Q1Multiple sources
“Confirmed Adjusted EPS guidance range of $7.00 to $7.20.”
- 2025-Q4Multiple sources
“Adjusted EPS guidance range of $7.00 to $7.20.”
- #3
Maintain revenue guidance of at least $400 billion
GrowthMaintain total revenue guidance of at least $400 billion for 2026.
BehindNewly stated in 2025-Q4. The company has set a revenue guidance of at least $400 billion for 2026. Revenue for 2025-Q4 was $82.586 billion, indicating a need for significant growth to meet the annual target.
Total revenues of at least $400.0 billion for 20260%CEO/CFO:“The Company is initiating its 2026 full-year financial guidance as follows: Total revenues of at least $400.0 billion.”Multiple sourcesSource dated 2025-12-09Stated 1 of last 8 quartersFirst seen 2025-12-09provisionalShow history (1)
- 2025-Q4Multiple sources
“The Company is initiating its 2026 full-year financial guidance as follows: Total revenues of at least $400.0 billion.”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
P/E over the last 5 years
67 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
CVS CVS Health | +16 | fair | moderate |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is cut (currently RAISED as of 2026-05-06)-16 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
- If rates state reverses from -0.37 (negative) to +0.37 (positive)-2.9 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-062d agoItem 2.02
by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (as amended, the “Exchange Act”) or otherwise subject to the liabilities of that Section, and shall not be or be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall…
earnings preannouncementnegativescore 75 - 2026-03-191mo agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d): On March 18, 2026, the Board of Directors (the “Board”) of CVS Health Corporation (“CVS Health” or the “Company”) elected John E. Gallina to serve on the Board, effective March 19, 2026. Mr. Gallina, age 66, is the former Executive Vice President and Chief Financial Officer (“CFO”) of Elevance Health, Inc. (“Elevance”; NYSE: ELV) a leading hea…
executive changeneutralscore 25 - 2026-02-102mo agoItem 2.02
by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (as amended, the “Exchange Act”) or otherwise subject to the liabilities of that Section, and shall not be or be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall…
earnings preannouncementneutralscore 9
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.